An Open Label, Multi-Center, Phase 2 Safety and Efficacy Study of Denosumab (AMG 162)
|Effective start/end date||2/23/06 → 6/30/12|
- Amgen Inc.
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.